A detailed history of Aviva PLC transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Aviva PLC holds 18,072 shares of HRMY stock, worth $683,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,072
Previous 17,386 3.95%
Holding current value
$683,844
Previous $694,000 10.52%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$31.86 - $41.49 $21,855 - $28,462
686 Added 3.95%
18,072 $621,000
Q3 2024

Nov 14, 2024

SELL
$30.0 - $39.95 $111,900 - $149,013
-3,730 Reduced 17.66%
17,386 $694,000
Q2 2024

Aug 02, 2024

BUY
$28.81 - $33.01 $38,749 - $44,398
1,345 Added 6.8%
21,116 $637,000
Q1 2024

May 14, 2024

SELL
$29.93 - $35.06 $14,216 - $16,653
-475 Reduced 2.35%
19,771 $663,000
Q4 2023

Feb 09, 2024

BUY
$19.2 - $33.78 $388,723 - $683,909
20,246 New
20,246 $653,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.24B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Aviva PLC Portfolio

Follow Aviva PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.